L. Pierre, . Physiologie, . Orthopédie, L. Maintien-À-domicile-isabelle, L. Pharmacologie-cardiovasculaire-dominique et al., Chimie physique générale Pharmacie galénique

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-joël et al., Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique

J. Olivier, . Toxicologie, K. Sécurité-sanitaire-francine, L. Pharmacie-galénique-alexandrine, B. Informatique et al., Chimie organique Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique PROFESSEUR ASSOCIE, Biochimie et Biologie

. Bibliographie1 and S. Sweetman, Azacitidine " p 529 In : Martindale : The complete drug reference, 2005.

R. Des, C. Du-produit, and «. Vidaza, 85 ème édition ; Paris : édition Maloine, 2009.

H. Autorité and D. Santé, Direction de l'évaluation médicale

P. Greenberg, C. Cox, M. Lebeau, P. Fenaux, P. Morel et al., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-88, 1997.

A. Guerci-bresler, L. Ades, E. Gyan, M. Mohty, L. Legros et al., Recommandations pour l'utilisation de l

. Pour-le-groupe-francophone-des-myélodysplasies, Février 2010. 26 pages, 2010.

A. Kornblith, J. Herndon, L. Silverman, E. Demakos, R. Odchimar-reissig et al., Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.20, issue.10
DOI : 10.1200/JCO.2002.04.044

X. Zhu, Y. Ma, and D. Liu, Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights, Journal of Hematology & Oncology, vol.3, issue.1, p.17, 2010.
DOI : 10.1186/1756-8722-3-17

URL : https://jhoonline.biomedcentral.com/track/pdf/10.1186/1756-8722-3-17?site=jhoonline.biomedcentral.com

G. Batty, H. Kantarjian, J. Issa, E. Jabbour, F. Santos et al., Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency, Clinical Lymphoma Myeloma and Leukemia, vol.10, issue.3
DOI : 10.3816/CLML.2010.n.032

Y. Cheung, B. Vishnuvajjala, N. Morris, and K. Flora, Stability of azacitidine in infusion fluids

D. Chatterji and J. Gallelli, Stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion, Journal of Pharmaceutical Sciences, vol.68, issue.7
DOI : 10.1002/jps.2600680709

D. Harting, J. Brandenburg, H. Vermeij, and P. , Stability of azacitidine in lactated Ringer's injection frozen in polypropylene syringes

M. Zhao, M. Rudek, P. He, C. Hartke, S. Gore et al., Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography, Journal of Chromatography B, vol.813, issue.1-2
DOI : 10.1016/j.jchromb.2004.09.012

I. Des, . Des, and .. Traités-par-l-'azacitidine, 16 II-1, ETUDE

S. Du and D. , 40 V-1.5.2. Spécificité vis-à-vis du mannitol, p.45

V. De and M. Suspension-d-'azacitidine-À-25, 54 VI-1, p.56